Dow Down0.25% Nasdaq Down0.14%

XOMA Corporation (XOMA)

4.27 0.06(1.39%) Sep 29, 4:00PM EDT
ProfileGet Profile for:
XOMA Corporation
2910 Seventh Street
Berkeley, CA 94710
United States - Map
Phone: 510-204-7200

Index Membership:N/A
Full Time Employees:180

Business Summary 

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on XOMA Corporation

Corporate Governance 
XOMA Corporation’s ISS Governance QuickScore as of Sep 1, 2014 is 5. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John W. Varian , 54
Chief Exec. Officer, Pres and Director
Mr. Patrick J. Scannon M.D., Ph.D., 66
Founder, Chief Scientific Officer, Exec. VP and Director
Mr. Fred Kurland , 63
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Sec.
Mr. Paul D. Rubin M.D., 60
Chief Medical Officer and Sr. VP of R&D
Mr. Thomas Klein , 52
Chief Commercial Officer and VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders